News >

Expert Explains Shifting Myeloma Paradigm

Angelica Welch
Published: Friday, Apr 27, 2018

Dr. Keith Stewart, MB ChB

Keith Stewart, MB ChB
In the shifting treatment landscape of multiple myeloma, experts are beginning to question previously established methods as new agents and techniques emerge.

State of the Science Summit™ on Multiple Myeloma and Myeloproliferative Neoplasms, Keith Stewart, MB, ChB, professor of medicine, consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, discussed the role of stem cell transplant, minimal residual disease (MRD) testing, and maintenance therapy in the treatment of patients with multiple myeloma.

Transplant

Agents such as the immunomodulatory drug lenalidomide (Revlimid) and the proteasome inhibitor bortezomib (Velcade) have entered the myeloma space, potentially changing the progression of treatment for these patients. Specifically, the role of transplant has come under question—a therapy that Stewart says is often intolerable for patients.
... to read the full story
To Read the Full Story



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x